Pancreatic cancer interception gains support from a newly approved drug and mouse evidence, as PRECEDE enrolls over 12,000 people
This Nature report surveys the latest progress in pancreatic cancer interception: after the FDA approved daraxonrasib (Rasonque) in August, the AACR pancreatic cancer meeting made interception a main theme, Simeone reported that PRECEDE has enrolled a little more than 12,000 people with more than 50 participants diagnosed with pancreatic cancer, many at the earliest stages, and set a goal of raising five-year survival from 13.7% to 50%, while Stanger's team showed in mice that giving a drug that disarms KRAS and related cancer-promoting proteins when tiny precancerous pancreatic growths appear improved survival.